SCHEMBL4931897

SCHEMBL4931897

CCOc1ccc(Nc2cc(Cl)c(Cl)cc2N)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
NFKB1 P19838 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.49
EHMT2 Q96KQ7 1/20 0.48
MAPT P10636 8/20 0.47
HTT P42858 3/20 0.46
NPC1 O15118 1/20 0.46
JAK2 O60674 1/20 0.46
RAB9A P51151 1/20 0.46
TSHR P16473 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 3/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
NQO1 P15559 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22683204 0.89 CTDSP1 (0.55) KDM4ENFKB1CTDSP1EHMT2MAPT
SCHEMBL4927439 0.88 MAPT (0.46) KDM4ENFKB1CTDSP1EHMT2MAPT
SCHEMBL4921551 0.88 UNG (0.45) KDM4EMAPTHTTNPC1RAB9A
SCHEMBL20269580 0.87 CTDSP1 (0.54) KDM4ENFKB1CTDSP1EHMT2MAPT
SCHEMBL27599836 0.85 KDM4E (0.48) KDM4ENFKB1CTDSP1EHMT2MAPT
SCHEMBL5188930 0.84 MAPT (0.57) KDM4ENFKB1CTDSP1EHMT2MAPT
SCHEMBL4932088 0.84 EHMT2 (0.56) KDM4ENFKB1CTDSP1EHMT2MAPT
SCHEMBL22102773 0.83 TSHR (0.59) KDM4ENFKB1CTDSP1EHMT2MAPT
SCHEMBL4933031 0.83 MAPT (0.57) KDM4EMAPTHTTNPC1RAB9A
SCHEMBL22102774 0.82 KMT2A (0.50) KDM4ECTDSP1EHMT2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 KDM4E 2237/4885NFKB1 1586/4885CTDSP1 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.